ReviewMediastinum (Hong Kong, China)2026
Recurrence and primary TETs: is it the same disease?-a narrative review.
Review in Mediastinum (Hong Kong, China), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Thymic epithelial tumors (TETs) present peculiar characteristics, with indolent behavior and excellent prognosis when treated. Based on these characteristics, also recurrence may present similar characteristics, but some aspects of their management should be interpreted and are still not well defined. The objective of this narrative review is to discuss peculiar aspects of primary and recurrent TETs showing how should be managed. Methods: A literature search was conducted using PubMed and Google Scholar to inform the narrative review. Eligible articles had to be published in English between January 1, 1991 to September 30, 2025. Key Content and Findings: The presentation of recurrent disease may show some differences compared with primary tumors. Many features are shared by primary TETs and their recurrences, with only limited changes in histology and genetic profiles that do not seem to significantly affect prognosis. Recurrences generally retain the characteristics of the original tumor, although they may exhibit greater clinical aggressiveness. Due to their clinically indolent behavior, these tumors are managed quite peculiarly. Indeed, surgery represents the cornerstone of treatment for these tumors and is often considered, even in cases of recurrence. Conclusions: Primary TETs and recurrences present similar characteristics that may be considered during treatment, even if in case of recurrence the more aggressive behavior should be taken into account.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.